source
- Revolution Medicines' Rasonque shows 42% response and 16-month survival in NSCLC subgroupData from a subgroup of an earlier trial, described by Truist Securities as the most relevant to Revolution Medicines' ongoing Phase 3 study, reported a 42% overall response rate and a median overa…
- GSK licenses Hutchmed's KRAS-EGFR antibody-drug conjugate for $110 million upfrontGSK announced it will pay $110 million upfront to obtain a license for a KRAS-EGFR antibody-drug conjugate developed by Chinese biopharma Hutchmed. The agreement also includes potential milestone p…